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The impact of community-acquired
pneumonia on the health-related quality-
of-life in elderly
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Abstract
Background: The sustained health-related quality-of-life of patients surviving community-acquired pneumonia has
not been accurately quantified. The aim of the current study was to quantify differences in health-related quality-of-
life of community-dwelling elderly with and without community-acquired pneumonia during a 12-month follow-up
period.
Methods: In a matched cohort study design, nested in a prospective randomized double-blind placebo-controlled
trial on the efficacy of the 13-valent pneumococcal vaccine in community-dwelling persons of ≥65 years, health-related
quality-of-life was assessed in 562 subjects hospitalized with suspected community-acquired pneumonia (i.e. diseased
cohort) and 1145 unaffected persons (i.e. non-diseased cohort) matched to pneumonia cases on age, sex, and health
status (EQ-5D-3L-index). Health-related quality-of-life was determined 1–2 weeks after hospital discharge/inclusion and 1,
6 and 12 months thereafter, using Euroqol EQ-5D-3L and Short Form-36 Health survey questionnaires. One-year quality-
adjusted life years (QALY) were estimated for both diseased and non-diseased cohorts. Separate analyses were
performed for pneumonia cases with and without radiologically confirmed community-acquired pneumonia.
Results: The one-year excess QALY loss attributed to community-acquired pneumonia was 0.13. Mortality in the
post-discharge follow-up year was 8.4% in community-acquired pneumonia patients and 1.2% in non-diseased persons
(p < 0.001). During follow-up health-related quality-of-life was persistently lower in community-acquired pneumonia
patients, compared to non-diseased persons, but differences in health-related quality-of-life between radiologically
confirmed and non-confirmed community-acquired pneumonia cases were not statistically significant.
Conclusions: Community-acquired pneumonia was associated with a six-fold increased mortality and 16% lower
quality-of-life in the post-discharge year among patients surviving hospitalization for community-acquired
pneumonia, compared to non-diseased persons.
Trial registration: ClinicalTrials.gov, NCT00812084.
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Background
Community-acquired pneumonia (CAP) causes consid-
erable disease and economic burden. In the Netherlands,
the overall incidence of CAP was estimated to be 295
per 100,000 inhabitants, yielding approximately 50,000
episodes per year, with considerable variation between
age-groups [1]. Approximately 45% of all CAP episodes
occur in persons aged ≥65 years [1]. In the period after
recovery, CAP is associated with higher risks on e.g.
stroke and other cardiovascular events [2, 3]. Both CAP
and the occurrence of these other diseases in the post-
discharge period may impact on the health-related
quality-of-life (HrQol). However, only limited data are
available on HrQol after a CAP episode [4]. In only two
of six studies that focused on HrQol after CAP [5–10]
patient follow-up exceeded 6 weeks. El Moussaoui et al.
[7] followed patients for 18 months using the Short-
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Form (36) Health survey [11] (referred hereafter as
SF36), and Honselmann et al. [10] determined the
HrQol at one-year post-discharge using the Euroqol EQ-
5D-3L instrument [12] (referred hereafter as EQ5D) in
patients that had survived an episode of pneumonia
and/or sepsis for which admission to intensive care was
needed. These studies were all descriptive, and none of
these studies quantified the excess quality-adjusted life-
years (QALY) lost due to CAP in comparison with non-
diseased persons (i.e. no pneumonia). The aim of the
current study was to quantify differences in HrQol of
community-dwelling elderly with and without CAP during
a 12-month follow-up period. In addition, possible HrQol
differences between radiologically confirmed and radio-
logically non-confirmed CAP cases were investigated.
Methods
Study design, setting and participants
The current study, “Costs, Health status and Outcomes
of CAP (Community-Acquired Pneumonia)” (CHO-
CAP), was executed in parallel to the “Community-Ac-
quired Pneumonia Immunization trial in Adults”
(CAPiTA) trial, a placebo-controlled double-blinded
RCT evaluating the effectiveness of a 13-valent pneumo-
coccal conjugate vaccine in 84,496 community-dwelling
elderly in the Netherlands [13, 14]. The CHO-CAP-
study used a nested matched-cohort study design when
recruiting patients hospitalized with a clinical suspicion
of a pneumonia episode from the CAPITA-study popu-
lation and prospectively followed them, along with non-
diseased subjects (i.e. no pneumonia), for a one-year
post-discharge period (Fig. 1) [15]. CAPiTA-participants
were approached for study participation in CHO-CAP at
the time of vaccination (November-2008-January-2010).
Overall, 72,074 CAPiTA-participants1 received the invi-
tation to return the CHO-CAP-baseline questionnaire
together with a signed informed consent form. Those
who returned both questionnaire and informed consent
formed the CHO-CAP source population (n = 47,4762).
This source population was a priori eligible for the
nested matched-cohort study. Within the CAPiTA-trial,
3225 patients with a suspected pneumonia were identi-
fied in 56 Dutch sentinel hospitals. Potential cases for
the “diseased”-cohort were subjects with a first-time sus-
pected pneumonia episode, participating in the CHO-
CAP source population, without recently diagnosed ma-
lignancy and able to complete questionnaires. After hos-
pital discharge, these subjects were invited for
participation in the diseased cohort. For feasibility rea-
sons, we included all patients hospitalized with a clinical
suspicion, which were later stratified upon either or not
receiving a radiological confirmation of CAP by the
blinded chest X-ray adjudication committee. Those who
consented were visited at home within 2 weeks of
hospital discharge by trained interviewers. They were
asked to complete self-administered questionnaires dur-
ing the home visit (day 0), and at 1, 6 and 12 months
after the home visit through postal questionnaires. For
each subject in the diseased cohort, two matched non-
diseased subjects (i.e. no pneumonia) were identified
from the CHO-CAP source population (referred here-
after as non-diseased subjects). Matching was based on
age, sex, and EQ-5D-3L-index collected at vaccination, im-
plying that health status of people with suspected pneumo-
nia and their matched non-diseased subjects was similar at
the time of vaccination. Non-diseased subjects adhered to
the same inclusion criteria as suspected pneumonia pa-
tients. They were asked to complete self-administered
questionnaires during the home visit (day 0). Further ques-
tionnaires were sent by regular mail 1, 6 and 12 months
after the home visit. For full details see Mangen et al. [15].
Definitions of subgroups
Additionally, we did distinguish between “radiologically
confirmed” CAP cases and the matched non-diseased
subjects and “radiologically non-confirmed” CAP cases
and their matched non-diseased subjects. A “radiologic-
ally confirmed” CAP was defined as the presence of two
or more clinical signs of pneumonia together with a
chest x-ray consistent with pneumonia, identical to the
definition used within the CAPiTA-trial [13].
Data collection
Date of birth, sex, place of residence, loss-to-follow-up due
to death during the follow-up period and causes of death
were extracted from the CAPiTA-study files [14]. Health
status (EQ5D) and socio-demographic status (living situ-
ation and education) were collected at the time of vaccin-
ation with the CHO-CAP-baseline questionnaire. Full
details of data collection of nested matched-cohort study are
provided in Mangen et al. [15]. In short, comorbidity details
were collected during the home visit. Current living situ-
ation was collected at all four contact moments. Health sta-
tus (EQ5D) was collected thrice for suspected pneumonia
cases during the home-visit interview, reflecting health sta-
tus (1) at day of interview, (2) at the worst moment during
the recent pneumonia episode, and (3) previous to the re-
cent pneumonia episode. Health status was also collected at
month 1, month 6 and month 12 after initial visit using both
EQ5D and SF-36. For non-diseased subjects, both EQ5D
and SF-36 were administered at all four contact moments.
For suspected pneumonia cases, clinical information on hos-
pital admission (e.g. X-ray result; clinical symptoms; length
of stay) was extracted from the CAPiTA-study files [14].
Health status questionnaires
The SF-36 is composed of 36-items measuring health
across eight domains (physical functioning, social
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functioning, role limitations with respect to physical
activities, role limitations with respect to emotional
activities, pain, mental health, vitality and general
health perception). Responses to each item within a
domain are combined to generate a score from 0 to
100, where 100 indicates best health [11]. Because of
the elderly population - some potentially in poor
health - the usual order of items in question 3 was
inversed [16]. Applying the scoring-method developed
by Brazier et al. [17], we further derived the SF-6D
health-index from the SF-36 survey, a numerical
index between 0 (“death”) and 1 (“full health”) [17].
The EQ5D consists of two parts, the EQ-5D-
descriptive system and the EQ-visual analogue scale
(VAS) [18]. The EQ-VAS records the participants’
self-reported health on a VAS from 0 (“Worst imagin-
able health state”) to 100 (“Best imaginable health
state”) [18]. The EQ5D-descriptive system consists of
five domains (mobility, self-care, usual activities, pain/
discomfort and anxiety/depression) and three func-
tioning levels (no problems, some problems or severe
problems) [12, 18]. The EQ5D health states were
scored with the Dutch value-set [19], to obtain EQ-
5D-3L summary indexes (EQ-index) ranging from 0
(“death”) to 1 (“full health”) [12, 19].
QALY estimations
Quality Adjusted Life Years (QALY) is a concept used to
reflect a year in full quality of life. Hence, QALYs com-
bine both length of life and quality of life. Quality of life
is represented in a value between 0 (death) and 1
(optimal quality of life). QALYs are estimated by multi-
plying length of life with the indicator value for quality
of life. One-year QALY estimates, with and without
pneumonia episode included, were calculated for both
cohorts, using the self-reported EQ5D health states and
its associated index values at the different contact mo-
ments based on recorded date of contact moment. An
area under the curve approach was followed by interpol-
ating between the observations provided by the patients.
For patients who died, we calculated QALY by using the
date of death and a utility score of 0 from that date on-
wards. For missing EQ-indexes, ten imputations were
performed. QALYs were calculated in each imputed
dataset and averaged over the ten imputated datasets.
The observed utility difference between both cohorts
was attributed to the CAP episode. Excess QALY loss
was calculated for the one-year post-discharge period,
excluding and including the CAP episode, respectively
(see Additional file 1: Figure S1A for illustration).
Additionally, we estimated the QALY and the excess
QALY loss for one-year survivors. Pairs of pneumonia
cases and non-diseased subjects in which one of the
three died during the follow-up were excluded from
these estimates.
Data analysis
Health status and QALY estimates in the suspected
pneumonia cases and non-diseased subjects are pre-
sented for the different follow-up moments, in a decom-
posed manner (i.e. at the level of the different domains
of quality of life) and as summary index. Causes of death
Fig. 1 Flow chart of CHO-CAP study. *Due to logistical reasons the first 14.7% of CAPiTA-participants were not invited to participate in the CHO-CAP study
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were categorized into five categories: (1) infectious dis-
eases; (2) chronic lung diseases; (3) cancer; (4) cardiovas-
cular events and stroke and (5) others. Depending on
the nature and distribution of data, we used Chi-square
test for categorical variables (e.g. sex, education) and
non-parametric tests for non-normally distributed vari-
ables (e.g. scores) to test for differences between both
cohorts (i.e. diseased and non-diseased cohort) and for
differences between patients with and without confirmed
CAP. Correlation between the different instruments was
studied using Spearman’s rank correlation coefficient.




Of the 3225 identified suspected pneumonia episodes in
the CAPiTA-trial, 1750 (54%) belonged to the CHO-
CAP source population, of which 562 (32%) participated;
341 (61%) had radiologically confirmed CAP and 221
(39%) had radiologically non-confirmed CAP (Fig. 1).
Reasons for non-participation/exclusion are provided in
in the Additional file 1: Table S1A.
Suspected pneumonia cases
Baseline characteristics of the suspected pneumonia
cases and their non-diseased subjects are summarized in
Table 1. Despite adequate matching on three criteria,
non-diseased subjects had fewer comorbidities, were
higher educated and were more often from the south of
the Netherlands than pneumonia cases (Table 1).
Compared to the non-diseased subjects, suspected
pneumonia cases more frequently died during the one-
year follow-up period (8.4% vs 1.2%;p < 0.001 (in the
Additional file 1: Figure S2A.); attributable risk:0.059(95%
CI:0.058–0.060)) or withdrew from the study (16.7% vs
9.9%; p < 0.001), mainly because of bad health (in the
Additional file 1: Table S2A). Chronic lung diseases, car-
diovascular events and stroke were more frequently
reported as being the cause of death for suspected pneu-
monia cases than for non-diseased subjects (p = 0.054; in
the Additional file 1: Table S2A)).
Figure 2 shows the distribution of suspected pneumo-
nia cases and non-diseased subjects reporting problems
in the five domains of the EQ5D-instrument at all obser-
vation moments. By definition, non-diseased subjects
and suspected pneumonia cases had a similar health sta-
tus at the moment of vaccination. However, during
follow-up suspected pneumonia cases more frequently
reported problems in the five domains of the EQ5D-
instrument than non-diseased subjects at all contact
moments and for all domains (Fig. 2). This finding was
confirmed by the SF36-questionnaire. Suspected pneu-
monia cases had persistently lower SF-36 mean scale
scores on all domains and during all contact moments,
compared to their non-diseased subjects (Fig. 3). Fur-
thermore, HrQol, as expressed in EQ5D and SF-6D
index value and EQ-VAS score of suspected pneumonia
cases was constantly lower than HrQol of non-diseased
subjects during the one-year follow-up (Table 2, in the
Additional file 1: Figure S3A). At month-12, HrQol-
scores were significantly lower for survivors in the sus-
pected pneumonia cohort compared to the non-diseased
cohort (EQ5D-index:0.74 vs 0.82(p < 0.001) and SF6D-
index:0.68 vs 0.75(p < 0.001)).
One-year QALY estimates, excluding the CAP episode
and using the self-reported EQ5D health status and its
associated-index values, were 0.68 and 0.81 for suspected
pneumonia cases and non-diseased subjects (p < 0.001),
yielding a utility difference between both cohorts of −0.13
attributable to suspected pneumonia. One-year QALY
estimates, including the CAP episode, were 0.67 and
0.81 for suspected pneumonia cases and non-diseased
subjects (p < 0.001), yielding an excess QALY loss of 0.15.
Slightly smaller QALY differences were obtained when
considering only survivors (Table 3), resulting in excess
QALY loss of 0.10, if excluding the CAP episode, and
0.11, if including the CAP episode, respectively.
EQ5D-index, EQ-VAS and SF6D-index were positively
correlated at all contact moments for suspected pneumo-
nia cases and non-diseased subjects (rho > 0.45), in the
Additional file 1: Table S3A and Table S4A. The highest
correlation was found between EQ5D-index and SF6D-
index for both suspected pneumonia cases and non-
diseased subjects (rho >0.67 for all contact moments).
Radiologically confirmed and non-confirmed CAP cases
There were apparent differences between patients with
radiologically confirmed and non-confirmed CAP, but
when repeating analyses in a stratified manner interpret-
ation did not change. Radiologically confirmed and non-
confirmed CAP cases did not differ in baseline charac-
teristics and were adequately matched to their non-
diseased subjects (in the Additional file 1: Table S5A).
Radiologically confirmed CAP cases stayed significantly
longer in hospital than radiologically non-confirmed
CAP cases, but had comparable median numbers of clin-
ical symptoms, pneumonia severity index (PSI) scores
[20], admissions to ICU and readmissions within 30 days,
Table 4. Mortality was higher for patients with radio-
logically confirmed CAP (10.3%) compared to non-
confirmed CAP (5.4%; p = 0.043), but the causes of death
were comparable (in the Additional file 1: Table S6A).
The attributable risks of dying, compared to non-
diseased subjects, were 0.083 (95%CI:0.082–0.084) for
those with radiologically confirmed CAP and 0.047
(95%CI:0.047–0.048) for those with non-confirmed CAP.
As compared to their non-diseased subjects, both
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Fig. 2 Profile of the population, using the EQ5D instrument: Percentage reporting any problems per domain at different contact moments for
the suspected pneumonia cases and the non-diseased subjets, respectively. Note: No significant difference at baseline (i.e. at vaccination) in any
domain. Significant differences (p < 0.05) for all domains on all contact moments during the follow-up period
Table 1 Baseline characteristics of suspected pneumonia cases and their non-diseased subjects
Suspected pneumonia cases (i.e. “diseased” cohortb) Non-diseased subjects p-value
Episodes/subjects 562 1123
Matching criteria
Male, in % 71.0 71.1 ns
Age at inclusiona, median (IQR) 76 (72–82) 76 (72–81) ns
EQ5D-index (at vaccination), median (IQR) 0.89 (0.78–1.00) 0.89 (0.78–1.00) ns
Other characteristics
Number of self-reported comorbidities
at inclusiona, median (IQR)
2 (1–4) 2 (1–3) <0.001










Living situation at vaccination, in % ns
Single household 27.6 26.8
Two or more person/household 71.5 72.8
Elderly home 0.7 0.4
Missing 0.2 0.1
Vaccinated, in % 48.4 51.6 ns
Abbreviations: SD, Standard deviation, ns not significant
aAt inclusion in cohort (= day of home visit). bComposed of radiologically confirmed CAP cases (i.e. having a positive X-rays and at least 2 clinical cri-
teria) and radiologically non-confirmed CAP cases
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Fig. 3 SF-36 mean scale scores at different contact moments for the suspected pneumonia cases and the non-diseased subjets, respectively.
Abbreviations: PF = Physical Function; RP = Role-Physical; BP = Bodily Pain; GH = General Health; VT = Vitality; SF = Social Functioning; RE = Role-
Emotional; MH =Mental Health
Table 2 EQ5D-index, EQ-VAS and SF6D-index for suspected pneumonia and the non-diseased subjects
Suspected pneumonia cases Non-diseased subjects p-value
Mean (SD)/Median (IQR) Missing/died Mean (SD)/Median (IQR) Missing/died
EQ5D-index
At vaccinationa 0.87 (0.16)/0.89 (0.78–1.00) 0/0 0.87 (0.16)/0.89 (0.78–1.00) 0/0 ns
Prior to illness onset 0.81 (0.23)/0.86 (0.78–1.00) 0/0 - - -
At admission 0.23 (0.32)/0.24 (−0.00–0.43) 0/0 - - -
During home visit 0.70 (0.26)/0.78 (0.52–0.89) 0/0 0.84 (0.18)/0.84 (0.78–1.00) 0/0 <0.001
Month 1 0.72 (0.24)/0.78 (0.65–0.89) 60/4 0.83 (0.17)/0.84 (0.78–1.00) 44/2 <0.001
Month 6 0.74 (0.23)/0.78 (0.66–0.89) 85/29 0.82 (0.18)/0.84 (0.78–1.00) 76/4 <0.001
Month 12 0.74 (0.23)/0.78 (0.67–0.89) 104/49 0.82 (0.18)/0.84 (0.78–1.00) 124/14 <0.001
EQ5D-VAS
Prior to illness onset 71 (15.3)/70 (60–80) 0/0 - - -
At admission 33 (16.0)/30 (20–41) 1/0 - - -
During home visit 62 (16.7)/65 (50–70) 0/0 76 (13.2)/80 (70–85) 3/0 <0.001
Month 1 64 (16.3)/65 (50–75) 62/4 76 (13.9)/79 (70–85) 37/2 <0.001
Month 6 65 (16.4)/70 (55–78) 86/29 74 (15.2)/75 (65–84) 73/4 <0.001
Month 12 64 (17.5)/69 (50–78) 98/49 75 (14.6)/75 (68–85) 122/14 <0.001
SF6D-index
During home visit - - 0.77 (0.13)/0.79 (0.66–0.88) 9/0 -
Month 1 0.65 (0.13)/0.63 (0.58–0.73) 81/4 0.76 (0.13)/0.77 (0.65–0.88) 69/2 <0.001
Month 6 0.68 (0.14)/0.66 (0.59–0.79) 99/29 0.75 (0.14)/0.75 (0.63–0.88) 116/4 <0.001
Month 12 0.68 (0.14)/0.66 (0.58–0.77) 122/49 0.75 (0.13)/0.75 (0.63–0.87) 149/14 <0.001
Abbreviations: SD Standard deviation, ns not significant
amatching criterion
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radiologically confirmed and non-confirmed CAP
cases had a significantly persistent lower HrQol, inde-
pendent of the instrument used (see in the Additional
file 1: Figure S4A-S6A and Table S7A.). The excess
QALY loss attributable to CAP was with 0.14 for
radiologically confirmed CAP cases and 0.12 for
radiologically non-confirmed CAP cases, of the same
magnitude, independent of radiological confirmation
of CAP (in the Additional file 1: Table S8A.).
Discussion
In immunocompetent elderly, hospitalization for sus-
pected pneumonia was associated with a six-fold higher
risk of mortality and an average loss of QALYs attribut-
able to pneumonia of 0.13 after 1 year, compared to
non-diseased subjects. Patients with radiologically con-
firmed CAP had a two-fold higher mortality risk than
those with radiologically non-confirmed CAP, but the
average loss of QALYs attributable to CAP among survi-
vors was comparable. The one-year QALY loss associ-
ated with a CAP episode (0.13, excluding the CAP
episode, and 0.15, including the CAP episode) is two-
fold higher than the QALY loss that we used [21] in a
cost-effectiveness analysis of pneumococcal vaccination
(0.071) and is more than tenfold higher than the QALY
loss used by Melegaro and Emunds [22] in 2004 and in
most cost-effectiveness studies conducted thereafter in
Western European countries (e.g. [23–26]), namely
0.004 for inpatient CAP and 0.0079 for bacteraemia.
These estimates of QALY loss were based on expert
opinion and not real-life data. Preventing a higher QALY
loss through pneumococcal vaccination by definition
contributes to more favourable cost-effectiveness of vac-
cination. For example using a QALY loss of 0.15 rather
than 0.07 would have resulted in a somewhat more
favourable incremental cost-effectiveness ratio of 8,200
€/QALY versus the 8,650 €/QALY presented in our
recently published cost-effectiveness analysis [21].
Although the difference in QALYs is relatively large, the
impact on the cost-effectiveness ratio is relatively
limited, as mortality has a much higher impact on the
cost per QALY gained than quality-of-life.
Strengths of this study include the rigid prospective
study design nested within a randomized double-blinded
placebo-controlled trial that created the possibility to
quantify the excess QALY lost due to CAP in community-
dwelling elderly using a one-year follow-up period. We also
conducted separate analyses for patients with radiograph-
ically confirmed CAP and those without confirmation.
To control for potential biases between pneumonia
cases and non-diseased subjects, subjects in both
cohorts were matched on age, sex and EQ5D-index as












One-year post-discharge 0.68 (0.01) 0.81 (0.01) −0.13
Pneumonia episode & one-year post-discharge 0.67 (0.01) 0.81 (0.01) −0.15
Only survivors
One-year post-discharge 0.72 (0.01) 0.82 (0.01) −0.10
Pneumonia episode & one-year post-discharge 0.71 (0.01) 0.82 (0.01) −0.11
Abbreviations: QALY quality-adjusted life years, SE standard error
Table 4 Clinical data of radiologically confirmed and radiologically non-confirmed CAP cases
Radiologically confirmed CAP cases Radiologically non-confirmed CAP cases p-value
Episodes/subjects 341 221
Positive chest X-ray, in % 100 0 a
Number of clinical criteria, median (IQR) 4 (3–5) 4 (3–5) ns
PSI score, median (IQR) 93 (80–111) 90 (78–108) ns
Admitted to ICU, in % 9.7 5.2 ns
Readmitted within 30 days, in % 5.0 3.6 ns
LOS in days, median (IQR)
At 1st admission, 8 (6–12) 7 (5–11) 0.006
Including readmission 8 (6–11) 7 (5–10) 0.011
Abbreviations: IQR interquartile range, ns not significant
aAccording to definition radiologically confirmed CAP cases had to have a positive X-rays
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collected at the time of vaccination. CAP patients had
slightly more comorbidities and a lower educational
level, factors known to be negatively associated with
health status [27–29]. The calculated excess QALY loss
might therefore be a slight overestimation of the attrib-
utable QALY loss. Furthermore, our study may have suf-
fered from a healthy participant effect, as the study
population consisted of subjects that were willing-to-
participate in a one-year follow-up study who may have
been healthier than the non-responding CAP patients.
Indeed, one of the major arguments to refuse participa-
tion was self-perceived bad health, and patients with a
recent cancer diagnosis were excluded as well. In a
sicker population, mortality attributable to CAP would
most likely have been higher. As a result, the observed
QALY loss attributable to CAP and the mortality risk
within the first year post-discharge may have been
underestimated.
Conclusion
The current study is the first that provides detailed
HrQol during the recovery process of hospitalized eld-
erly suspected pneumonia patients for a one-year post-
discharge period using the EQ5D and SF36 question-
naires. It further provides a QALY loss attributable to
CAP for community-dwelling elderly, which is a neces-
sity for economic analyses targeted at preventing pneu-
monia infections and as such contributes to more
realistic future estimates of cost-effectiveness of prevent-
ive interventions for this infection. The CAP episode is
the onset of sustained loss of quality-of-life, with an
estimated difference in QALY of 16–18% between CAP
patients and their non-diseased subjects.
Endnotes
1Due to logistical reasons the first 14.7% of CAPiTA-
participants were not invited to participate in the CHO-
CAP-study.
248,634 participants returned the questionnaire with
signed informed consent. For 47,476 participants (97%)
an EQ5D-score could be estimated.
Additional file
Additional file 1: Figure S1A. Observed EQ-5D indexes for suspected
pneumonia cases and non-diseased subjects during the one-year post-
discharge period, excluding the CAP episode. Figure S2A. Survivors (%)
in the diseased cohort (i.e. suspected pneumonia cases) and the non-
diseased cohort during the one-year follow-up. Figure S3A. Mean EQ-
5D-3 L-index, EQ-VAS and SF6D-index at different contact moments for
the suspected CAP cases and the non-diseased subjects, respectively.
Figure S4A. Profile of the population using EQ5D-instrument: Percentage
reporting any problems per domain at different contact moments for A)
the radiologically confirmed CAP cases and their non-diseased subjects,
and B) the radiologically non-confirmed CAP cases and their non-
diseased subjects, respectively. Figure S5A. SF-36 mean scale scores at
different contact moments for A) the radiologically confirmed CAP cases
and their non-diseased subjects, and B) the radiologically non-confirmed
CAP cases and their non-diseased subjects, respectively. Figure S6A.
Mean EQ-5D-3 L-index, EQ-VAS and SF6D-index at different contact mo-
ments for the radiologically confirmed CAP cases and their non-diseased
subjects (A), and for the radiologically non-confirmed CAP cases and their
non-diseased subjects (B). Table S1A. Exclusion criteria and reasons for
nonparticipation in the “diseased” cohort of eligible suspected pneumo-
nia episodes. Table S2A. Living situation, loss-to-follow up and deaths of
suspected pneumonia cases and non-diseased subjects during the one-
year follow-up. Table S3A. Spearman’s rho for EQ-VAS, EQ5D-index and
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